| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11030706 | Atherosclerosis | 2018 | 40 Pages |
Abstract
Alirocumab is generally well-tolerated and effective with a similar safety profile in high-risk patients with or without prior revascularization (PCI/CABG).
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Dean J. Kereiakes, Norman E. Lepor, Robert Gerber, L. Veronica Lee, Joe Elassal, Desmond Thompson, C. Michael Gibson,